Table 2.
Baseline procedural characteristics.
| Characteristics | AF patients (n = 112) | Control group (n = 111) |
|---|---|---|
| ACS patients | 17 (15.18%) | 14 (12.16%) |
|
| ||
| Number of drug-eluting stents | ||
| 1 | 96 (85.71%) | 84 (75.68%) |
| 2 | 16 (14.29%) | 26 (23.42%) |
| ≥3 | 0 (0%) | 1 (0.90%) |
|
| ||
| PCI vessel | ||
| LAD | 61 (54.46%) | 74 (66.67%) |
| LCX | 18 (16.07%) | 30 (27.03%) |
| RCA and other vessels | 33 (29.46%) | 7 (6.31%) |
|
| ||
| Periprocedural treatment | ||
| Antiplatelet agent | 112 (100%) | 111 (100%) |
| GPIIbIIIa | 20 (17.86%) | 25 (22.52%) |
| Anticoagulants | 109 (97.32%) | 20 (18.02%) |
| β-Blocker | 95 (84.82%) | 97 (87.39%) |
| Statin | 105 (93.75%) | 107 (96.40%) |
| ACEI/ARB/ARNI | 59 (52.68%) | 48 (43.24%) |
Data are expressed as n (%). ACS, acute coronary syndrome; GPIIbIIIIa, glycoprotein IIbIIIa receptor blocker; LAD, left anterior descending artery; LCX, left circumflex artery; LM, left main coronary artery; PCI, percutaneous coronary intervention; RCA, right coronary artery. Antiplatelet agent refers to aspirin and clopidogrel or ticagrelor. Anticoagulants refer to warfarin or low molecular heparin or novel oral anticoagulant. ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNI, angiotensin receptor-neprilysin inhibitor.